Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/CCO.0000000000000749 | DOI Listing |
Eur Radiol
December 2024
Department of Radiology, Beaujon Hospital, AP-HP.Nord, Clichy, France.
Objectives: This study evaluates the prognostic value of tumor response on CT at 3 months, assessed by Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), and Liver Imaging Reporting and Data System Treatment Response Algorithm (LR-TRA) in patients with hepatocellular carcinoma (HCC) treated with selective internal radiation therapy (SIRT).
Materials And Methods: A retrospective analysis was conducted on 102 HCC patients treated with SIRT between 2018 and 2020. RECIST, mRECIST, and LR-TRA were assessed at 3 months post-SIRT.
Front Nucl Med
October 2023
Department of Nuclear Medicine, University of Pretoria, Steve Biko Academic Hospital, Pretoria, South Africa.
Hepatocellular carcinoma (HCC) is a major global health problem. Theragnostic is a term that refers to the integration of diagnostic and therapeutic modalities into a single system for personalized medicine. Theragnostic care in HCC involves the use of imaging techniques to diagnose the cancer and assess its characteristics, such as size, location, and extent of spread.
View Article and Find Full Text PDFWorld J Gastrointest Oncol
September 2024
Department of Radiology, Interventional Medical Center, Science and Technology Innovation Center, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
With continuous advancements in interventional radiology, considerable progress has been made in transarterial therapies for hepatocellular carcinoma (HCC) in recent years, and an increasing number of research papers on transarterial therapies for HCC have been published. In this editorial, we comment on the article by Ma published in the recent issue of the "Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable HCC". We focus specifically on the current research status and future directions of transarterial therapies.
View Article and Find Full Text PDFJ Gastrointest Oncol
August 2024
Division of Interventional Radiology, Department of Medical Imaging, University of Arizona, Tucson, AZ, USA.
Cardiovasc Intervent Radiol
September 2024
Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!